Immutep Limited, a biotech company focusing on the creation of innovative LAG-3 immunotherapies for cancer and autoimmune diseases, has recently announced preliminary topline results. These results originate from the TACTI-003 Phase IIb clinical trial, which tests the effectiveness of eftilagimod alpha (or efti). Efti is used in combination with KEYTRUDA, also known as pembrolizumab, an anti-PD-1 therapy developed by MSD. The combination is considered as a potential initial treatment for patients experiencing recurrent metastatic head and neck squamous cell carcinoma, especially those who show negative PD-L1 expression.
In immuno-oncology, the therapy combination created by Immutep and MSD has been found to have an overall response rate of 26.9% and a disease control rate (DCR) of 57.7%. This range is based on a study of 26 patients whose tumors do not exhibit PD-L1 (with a Combined Positive Score of less than 1). According to RECIST 1.1 metrics, these rates are deemed favorable when compared with historical controls.
Speaking on the results, Dr. Martin Forster, of UCL Cancer Institute, University College London Hospital NHS Foundation and a TACTI-003 Investigator, said, "The preliminary topline results are encouraging, particularly for patients with head and neck squamous cell cancers who do not show PD-L1 expression. This type of cancer is incredibly varied, and there is a significant medical need to find solutions for all kinds of patients, irrespective of PD-L1 expression. It is especially crucial for those whose tumors do not express PD-L1 and are unable to receive chemotherapy. The potential for efti to work cohesively with MSD's KEYTRUDA to augment clinical responses and broaden the responsive patient base—without employing chemotherapy—is promising."
